GRAIL (NasdaqGS:GRAL) Q1 2026 Results in Focus

GRAIL (NasdaqGS:GRAL) opened 2026 with Q1 revenue of US$40.8 million, a basic EPS loss of US$2.29 and net income loss of US$93.2 million, setting a cautious tone against a share price of US$62.75. Over recent quarters the company has seen revenue move from US$31.8 million in Q1 2025 to US$40.8 million in Q1 2026. Quarterly basic EPS losses have ranged between US$2.29 and US$3.18, keeping the spotlight firmly on how quickly the business model can support more efficient margins.

See our full analysis for GRAIL.

With the headline numbers on the table, the next step is to line them up against the key stories investors already hold about GRAIL to see which narratives the latest margins support and which ones start to look stretched.

Losses Still Heavy Against US$156.1 Million TTM Revenue

• Over the last twelve months, GRAIL generated US$156.1 million of revenue but recorded a net loss of US$395.3 million and trailing basic EPS of US$10.31 in losses, showing that even with revenue growth the business is still burning a lot of cash to operate.
• Consensus narrative expects revenue to grow around 25.8% a year while losses have narrowed by about 6.3% a year over five years. This quarter's US$93.2 million loss sits against that backdrop of improving but still very negative earnings.
  • Analysts looking at that 6.3% yearly improvement in losses on a five year view are effectively saying the business has been moving toward smaller losses, yet the latest trailing twelve month net loss of US$395.3 million shows that profitability is still a long way off.
  • With consensus also expecting the company to remain unprofitable over the next three years, the combination of US$156.1 million in revenue and large losses is a clear reminder that the path from growth to earnings is not reflected in the current figures yet.

High 16.5x P/S Versus Peers And Industry

• The stock trades on a P/S of 16.5x compared with 10.8x for the US biotechs industry and 4.4x for peers, so the market is paying a higher multiple of GRAIL's US$156.1 million trailing revenue than it is for many competitors.
• Bears point out that this premium P/S sits alongside continued losses and an expectation that earnings will decline about 4.9% a year over the next three years, which raises questions about how much of the future growth story is already priced in.
  • On one side, analysts' consensus price target of US$67.71 is only modestly above the current US$62.75 share price, suggesting limited upside based on current models, while the valuation multiple of 16.5x sales is already above sector and peer averages.
  • On the other side, the same forecasts call for revenue growth of roughly 24.1% to 25.8% a year while the company is expected to stay loss making, so critics highlight that investors are paying up today without seeing a forecast path to profitability in that three year window.

Skeptics argue that paying 16.5x sales for a company expected to remain unprofitable and face earnings declines puts extra pressure on execution, so it helps to see how cautious investors are framing the story in full 🐻 GRAIL Bear Case.

Volatile Stock With Ongoing Dilution And Insider Selling

• Recent analysis flags a highly volatile share price over the last three months alongside shareholder dilution and significant insider selling in the past year, which all sit on top of a trailing twelve month net loss of US$395.3 million.
• Bullish investors focus on revenue growth forecasts of about 24.1% a year and the improvement in losses of 6.3% a year over five years, and see that as justification for looking past volatility and dilution, but the current earnings profile creates tension with that optimistic stance.
  • Supporters of the bullish narrative highlight that analysts expect revenues to reach around US$310.9 million by 2029 with earnings of US$41.1 million if margins reach industry levels, yet today the company is still reporting quarterly losses such as US$93.2 million in Q1 2026 and trailing twelve month losses of US$395.3 million.
  • At the same time, the stock already trades on a 16.5x P/S and analysts assume shares outstanding grow 7% a year, so anyone leaning bullish has to be comfortable with more dilution and an already full multiple while waiting for those longer term margin assumptions to play out.

If you want to see how supporters connect the current US$395.3 million trailing loss to that longer term growth story, it is worth reading the detailed bullish case side by side with the numbers 🐂 GRAIL Bull Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for GRAIL on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing mixed signals in the story so far is normal. This is exactly when looking at the raw numbers yourself can help you move fast and form a clear view using our breakdown of 2 key rewards and 5 important warning signs

Explore Alternatives

GRAIL is still carrying heavy losses alongside a high 16.5x P/S multiple, with ongoing dilution and volatility putting extra pressure on the current story.

If that mix of steep losses, rich valuation and bumpy trading feels like a lot to tolerate, it is worth checking stocks filtered for 74 resilient stocks with low risk scores as a calmer starting point.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.